<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384733</url>
  </required_header>
  <id_info>
    <org_study_id>The Skagen Trial 1</org_study_id>
    <nct_id>NCT02384733</nct_id>
  </id_info>
  <brief_title>Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost</brief_title>
  <official_title>The Skagen Trial 1, Moderately Hypofractionated Loco-regional Adjuvant Radiation Therapy of Early Breast Cancer Combined With a Simultaneous Integrated Boost: a Randomised Clinically Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the difference in late radiation morbidity between&#xD;
      hypofractionated and normofractionated loco-regional breast irradiation irrespective of&#xD;
      mastectomy or lumpectomy. In patients who a candidates for a boost, the boost will be&#xD;
      provided as a simultaneous integrated boost.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomization is between 50 Gy / 25 fractions and 40 Gy/15 fractions, 5 fractions weekly.&#xD;
      In patients treated with boost 2 dose levels are accepted: 16 Gy/8 fractions and 10 Gy/5&#xD;
      fractions. These boost treatments will be provided as simultaneous integrated boost, where&#xD;
      the overall treatment time in general is shortened 5 days. Thus the dose levels for boost&#xD;
      patients are:&#xD;
&#xD;
      63 Gy / 51.52 Gy / 28 fractions, 57 Gy / 50 Gy / 25 fractions, 52.2 Gy / 42.3 Gy / 18&#xD;
      fractions, and 45.75 Gy / 40 Gy / 15 fractions.&#xD;
&#xD;
      The primary endpoint is arm lymphedema 3 years after radiation therapy, but other late&#xD;
      radiation morbidities will also be evaluated along with recurrence and sites of recurrence.&#xD;
      Follow up of morbidity will continue for 10 years.&#xD;
&#xD;
      The hypothesis is that women operated for early breast cancer with indication for&#xD;
      loco-regional radiation therapy can be offered moderately hypofractionated therapy without&#xD;
      developing more late radiation induced morbidity compared to normofractionated radiation&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">July 1, 2032</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of ipsilateral arm lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>&gt;=10% increased arm circumference compared to the other arm defines edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrosis grade 2-3</measure>
    <time_frame>3 years</time_frame>
    <description>Breast or chest wall induration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm range of motion</measure>
    <time_frame>3 years</time_frame>
    <description>Impaired shoulder movement is present when &gt;20 degrees difference between arms at flexion and/or abduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of dyspigmentation</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse dyspigmentation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Any recurrence location and time to event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of pain in the irradiated area</measure>
    <time_frame>3 years</time_frame>
    <description>Pain in the irradiated area measured on visual analog scale compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensibility</measure>
    <time_frame>3 years</time_frame>
    <description>Change in sensibility in the irradiated area compared to baseline measured as yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of edema on breast / chest wall</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of telangiectasia in irradiated area</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse telangiectasia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2963</enrollment>
  <condition>Lymphedema</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Hypofractionated loco-regional RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normofractionated loco-regional RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Loco-regional RT</intervention_name>
    <arm_group_label>Hypofractionated loco-regional RT</arm_group_label>
    <arm_group_label>Normofractionated loco-regional RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Operated for early node-positive breast cancer with indication for loco-regional breast&#xD;
        radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Previous radiotherapy to chest wall, pregnant/lactating, comorbidity which may hinder 10&#xD;
        years follow up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Stenbygaard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troels Bechmann, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mette Nielsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitte Offersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanne Nielsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Kamby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sami Al-Rawi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Naestved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mechthild Krause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität Dresden Klinik und Poliklinik für Strahlentherapie und Radioonkologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Schreiber, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für Strahlentherapie, Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingvil Mjaaland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stavanger Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanja Marinko, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Oncology Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carine Kirkove, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiotherapy Department Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egil Blix, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of North Norway, Tromsoe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Unn-Miriam Kasti</last_name>
    <role>Study Chair</role>
    <affiliation>Kristiansand Hospital, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Birgitte Offersen</investigator_full_name>
    <investigator_title>MD, professor, ph.d.</investigator_title>
  </responsible_party>
  <keyword>Radiation induced morbidity, recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

